An­a­lysts throw cold wa­ter on Ex­elix­is and Roche's prostate can­cer da­ta, putting the pair a fur­ther step be­hind No­var­tis

Ex­elix­is has block­buster dreams for its Cabome­tyx drug, and it’s look­ing to cap­i­tal­ize in the prostate can­cer mar­ket by com­bin­ing it with Roche’s Tecen­triq. But af­ter a new da­ta read­out Mon­day drew con­cerns from an­a­lysts, its fu­ture in the area ap­pears more cloudy.

The ques­tions arose af­ter Ex­elix­is re­port­ed da­ta from a Phase Ib co­hort study­ing the Cabome­tyx and Tecen­triq com­bo in metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer, in­clud­ing 101 in­di­vid­u­als clas­si­fied as high-risk pa­tients. In this pop­u­la­tion, Ex­elix­is re­port­ed two re­sponse rates: one con­duct­ed by in­ves­ti­ga­tors show­ing an ORR of 27%, and one as­sessed by a blind­ed in­de­pen­dent ra­di­ol­o­gy com­mit­tee that showed an 18% ORR.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER